Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 285Prostatic Neoplasms 208Neoplasms 202Neoplasm Metastasis 179Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 157Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 104Carcinoma, Renal Cell 104Brain Neoplasms 89Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 84Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Menstruation Disturbances × Clear all
NCT02865915 2021-02-01

MLE4901 vs. Placebo for the Treatment of PCOS

Millendo Therapeutics, Inc.

Phase 2 Terminated
55 enrolled 10 charts

Acne Vulgaris, Alopecia, Hirsutism, Menstruation Disturbances, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡